Sfoglia per RIVISTA
FUTURE ONCOLOGY (LONDON, ENGLAND)
Collezione AOU San Luigi di Orbassano

  

Items : 18

HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. in Future oncology (London, England) / Future Oncol. 2024 May;20(15):969-980. doi: 10.2217/fon-2023-0602. Epub 2023 Dec 14.

2024
AOU San Luigi di Orbassano

Meng J; Sternberg DW; Fougeray R; Fan PD; Wu YL; Steuer C; Reck M; Novello S; Nishio M; Jänne PA; Mok T; Esker S; Yu HA;

Extension of lymph node dissection in the surgical treatment of esophageal and gastroesophageal junction cancer: seven questions and answers. in Future oncology (London, England) / Future Oncol. 2023 Feb;19(4):327-339. doi: 10.2217/fon-2021-0545. Epub 2023 Mar 21.

2023
AOU Città della Salute di Torino
AOU San Luigi di Orbassano

Migliore M; Degiuli M; Papis D; Vagliasindi A; Franco FD;

A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. in Future oncology (London, England) / Future Oncol. 2021 Oct;17(30):3987-3994. doi: 10.2217/fon-2020-1298. Epub 2021 Jul 19.

2021
AOU San Luigi di Orbassano

Ferro M; Lucarelli G; de Cobelli O; Dolce P; Terracciano D; Musi G; Porreca A; Busetto GM; Del Giudice F; Soria F; Gontero P; Cantiello F; Damiano R; Crocerossa F; Abu Farhan AR; Autorino R; Vartolomei MD; Marchioni M; Mari A; Minervini A; Longo N; Celentano G; Chiancone F; Perdonà S; Del Prete P; Ditonno P; Battaglia M; Zamboni S; Antonelli A; et alii...

Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):807-815. doi: 10.2217/fon-2020-0391. Epub 2021 Jan 29.

2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli

Cortesi E; Spada M; Salgarello M; Pignata S; Borsatti E; Zichi C; Filice A; Murabito A; Fanti S; Biasco E; Palermo A; Alongi P; Alongi F; Bortolus R; Facchini G; Baldari S; Tucci M; Pinto C; Monari F; Sbrana A; Costa RP; Vincentis G; Caffo O; Frantellizzi V;

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):763-773. doi: 10.2217/fon-2020-0935. Epub 2020 Nov 5.

2021
AOU San Luigi di Orbassano

Novello S; F Loong HH; Lin BK; Lin AB; Sashegyi A; Soldatenkova V; Davis HM; Elamin Y; Wolf J; Park K; Drilon A; Zhou CC; Solomon BJ; Arriola E; Pérol M; Goto K; Santini FC;

What does the future hold for the Lung Cancer Ambition Alliance project: an interview with Giorgio Scagliotti. in Future oncology (London, England) / Future Oncol. 2020 Mar;16(7):221-223. doi: 10.2217/fon-2019-0738. Epub 2020 Feb 5.

2020
AOU San Luigi di Orbassano

Scagliotti G;

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review. in Future oncology (London, England) / Future Oncol. 2019 Mar;15(9):989-994. doi: 10.2217/fon-2018-0469. Epub 2019 Jan 25.

2019
AOU San Luigi di Orbassano
ASL Cuneo 1

Colonese F; Canova S; Toschi L; Cerea G; Vavalà T; Tiseo M; Bidoli P; Cortinovis DL; Abbate MI;

Nilotinib in the treatment of chronic myeloid leukemia. in Future oncology (London, England) / Future Oncol. 2019 Mar;15(9):953-965. doi: 10.2217/fon-2018-0468. Epub 2018 Dec 14.

2019
AOU San Luigi di Orbassano

Sacha T; Saglio G;

Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. in Future oncology (London, England) / Future Oncol. 2019 Jul;15(21):2543-2553. doi: 10.2217/fon-2018-0772. Epub 2019 Jun 26.

2019
AOU San Luigi di Orbassano

Locati LD; Di Giannantonio V; Sbrana A; Musettini G; Sonetto C; Bironzo P; Botta L; Bossi P; Di Maio M; Antonuzzo A;

Long-term disease control and high clinical benefit in a patient with advanced thyroid cancer treated with lenvatinib. in Future oncology (London, England) / Future Oncol. 2019 Aug;15(24s):3-6. doi: 10.2217/fon-2019-0092. Epub 2019 Aug 6.

2019
AOU San Luigi di Orbassano

Scagliotti GV; Sperone P; Muratori L;

Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2019 Apr;15(10):1115-1123. doi: 10.2217/fon-2018-0715. Epub 2019 Mar 19.

2019
AOU San Luigi di Orbassano

Veccia A; Rossetti S; Mucciarini C; Conteduca V; Basso U; Chiuri VE; Guida A; Calvani N; Buttigliero C; Donini M; Ferraù F; Morelli F; Biasco E; Facchini G; Caffo O; Maines F; Kinspergher S; De Giorgi U;

Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment? in Future oncology (London, England) / Future Oncol. 2018 May;14(12):1223-1231. doi: 10.2217/fon-2017-0627. Epub 2018 Apr 27.

2018
AOU San Luigi di Orbassano

Tampellini M; Bironzo P; Di Maio M; Scagliotti GV;

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441. Epub 2017 Nov 14.

2018
AOU San Luigi di Orbassano

Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; Cecere FL; Giannarelli D; Luciani A; Bearz A; Tuzi A; Scotti V; Tonini G; Galetta D; Carta A; Soto Parra H; Rebonato A; Morabito A; Chiari R;

Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives. in Future oncology (London, England) / Future Oncol. 2018 Dec;14(29):3073-3083. doi: 10.2217/fon-2018-0287. Epub 2018 Aug 15.

2018
AOU San Luigi di Orbassano

Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM;

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.

2016
AOU San Luigi di Orbassano
ASL Torino 5

Santini D; Messina C; Perin A; Lodde M; Fratino L; Berruti A; Mucciarini C; Nicodemo M; Bonetti A; Alesini D; Zucali PA; Vicario G; Massari F; Lo Re G; Donini M; Bortolus R; Spizzo G; D'Angelo A; Zagonel V; Procopio G; Mattioli R; Mansueto G; Facchini G; Aieta M; Scognamiglio F; Ortega C; Di Lorenzo G; Caffo O; De Giorgi U; et alii...

Metastatic castration-resistant prostate cancer: time for innovation. in Future oncology (London, England) / Future Oncol. 2015;11(1):91-106. doi: 10.2217/fon.14.145.

2015
AOU San Luigi di Orbassano

Tucci M; Scagliotti GV; Vignani F;

First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. in Future oncology (London, England) / Future Oncol. 2014 May;10(6):1081-93. doi: 10.2217/fon.13.247.

2014
AOU San Luigi di Orbassano

Capelletto E; Novello S; Scagliotti GV;

Lung cancer and women. in Future oncology (London, England) / Future Oncol. 2008 Oct;4(5):705-16. doi: 10.2217/14796694.4.5.705.

2008
AOU San Luigi di Orbassano

Novello S; Vavalà T;